Regeneron announces publication of one-year results from PULSAR and PHOTON trials
March 10th 2024Results show Eylea HD extended dosing regimens were non-inferior to aflibercept 2 mg injection (Eylea) for both the treatment of wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).
Read More
Fortifeye launches Eye Pressure and Neuro Cognitive Support supplement
March 4th 2024The supplement is specifically crafted to promote healthy intraocular pressure (IOP), nurturing the well-being of retinal ganglion cells, and sustain the health of the retinal nerve fiber layer while boosting memory and concentration.
Read More
EnVision Summit 2024: Using the miCOR 700 device for phacoemulsification cataract surgery
February 21st 2024Anthony Mai, MD, shared results from using the miCOR 700 device, which is a new device from Zeiss, for phacoemulsification cataract surgery at the EnVision Summit 2024. He spoke with Peg Achenbach, OD, FAAO, Executive Director/Global Ambassador Strategies, Ophthalmology and Optometry at MJH Life sciences, on location in Puerto Rico to share more about his presentation.
Read More
Kyowa Kirin enrolls first patient in phase 2 trial of drops for treatment of diabetic macular edema
February 11th 2024The trial will evaluate tivozanib eye drops (KHK4951), a small-molecule vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3 tyrosine kinase inhibitor (TKI), in patients in with DME.
Read More
Angiogenesis 2024: Utilizing longitudinal AI-based fluid quantification for at-home monitoring
February 3rd 2024In conversation with Ophthalmology Times Europe, Anat Loewenstein, MD, illuminates the outcomes of using an AI-based fluid quantification for remote retina monitoring and analysis.
Read More
Advancements in ophthalmology: A comprehensive look at the FDA's 2023 approvals
December 19th 2023Ophthalmology witnessed a transformative year with 12 FDA approvals. As the year concludes, there remains a robust pipeline of drugs, setting high expectations for continued advancements in ophthalmological care in 2024 and beyond.
Read More
Curing genetic blindness with space-enhanced artificial retinas
December 12th 2023LambdaVision seeks to cure genetic blindness with a protein-based artificial retina. Harnessing microgravity in low-Earth orbit, the company collaborates with NASA and the ISS to perfect its manufacturing process.
Read More
AAO 2023: Real-world outcomes for faricimab for AMD
November 27th 2023Sophie Bakri, MD, spoke with the Ophthalmology Times team about her presentation at this year's American Academy of Ophthalmology meeting titled, "Real world outcomes and treatment patterns with faricimab and AMD FA retina."
Read More
AAO 2023: AVD-104 and the results of the phase II/III part 1 SIGLEC trial
November 26th 2023Mohammed Genead, MD, CEO of Aviceda spoke with the Ophthalmology Times team about the company's Phase II/III SIGLEC trial part 1 results, which were shared at this year's American Academy of Ophthalmology meeting.
Read More
AAO 2023: Post-hoc analysis of the YOSEMITE and RHINE clinical trials
November 24th 2023Marco A. Zarbin, MD, spoke with the Ophthalmology Times team about conducting a post-hoc analysis of the YOSEMITE and RHINE clinical trials and presenting the results at this year's American Academy of Ophthalmology meeting.
Read More